

January 5, 2016



Actinium Pharmaceuticals to Present at Biotech Showcase 2016

Live Webcast on January 11, 2016 at 9:30 am PT

NEW YORK, NY -- (Marketwired) -- 01/05/16 -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium"), a biopharmaceutical company developing innovative drug candidates for the treatment of advanced cancers, today announced that the Company will be presenting at the 8th Annual Biotech Showcase on Monday, January 11, 2016 at 9:30 am Pacific Time in Room Market Street. The Biotech Showcase is taking place on January 11 - 13, 2016 and is being held at the Parc 55 Hotel in San Francisco, California.

A live webcast of Actinium's presentation can be viewed via the following link that will also be on the Company's investor relations page <http://edge.media-server.com/m/p/jjeezy6>.

Actinium's management will host one-on-one meetings with conference attendees at Biotech Showcase 2016, which can be scheduled through the partnering360[®] system.

http://www.ebdgroup.com/bts/index.php?source=apisrc_ebd_group&utm_source=EBD%20Group&utm_medium=web&utm_campaign=

Additional information on Biotech Showcase 2016 can be found here <http://www.ebdgroup.com/bts/index.php>.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate lomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of lomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current

expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT:

Steve O'Loughlin

Senior Director, Finance and Corporate Development

Actinium Pharmaceuticals, Inc.

soloughlin@actiniumpharma.com

Source: Actinium Pharmaceuticals